Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-06-18

Accelerated Development of Vaccine benefit-risk Collaboration in Europe

Obiettivo

Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.

Approach: To achieve this vision through a public-private partnership, ADVANCE partners
1. establish common grounds and rules for collaboration between public and private stakeholders for best practice conduct of studies on the benefit-risk of vaccines.
2. map and promote synergies with pertinent other initiatives to maximize utilization of foreground and identification of gaps for program strengthening.
3. profile data sources that will yield rapid access to burden of disease, vaccine coverage, and benefits and risks of vaccines
4. adaptat and develop new methods for integrated benefit/risk assessment
5. create the ADVANCE phase I and phase II data platforms to evaluate a code of conduct, data sources, and methods developed in other WPs via a series of public-private co-operative studies proof-of-concept studies.

ADVANCE partners embrace the enormous potential to improve public health across European Member States by collaboratively utilizing the rich information generated in clinical routine care and captured in health care databases. While the ADVANCE Forum concept engages all stakeholder groups in a parliament-like structure, specific representative committees drive the innovative progress. Specific attention will be given to workflows depending on the level of urgency and on who is requesting utilization of the framework: regulatory authorities, vaccine manufacturers, public health organizations.

ADVANCE partners leverage their recent pioneering achievements in establishing operative technological platforms, developing pharmaco-epidemiological methods for burden of disease, coverage, effectiveness and risk. ADVANCE partners also build on a track record of delivering results of ground breaking international collaborative studies of unprecedented population size. ADVANCE capitalizes on these achievements and tailors structures and processes to the needs of collaborative public-private vaccine benefit-risk assessment. ADVANCE partners will provide access to data on more than 40 million subjects for testing of methods and immediate studies.

The existing technical platform boosted by the strong connection to the IMI EMIF project and many other synergistic initiatives will allow ADVANCE to focus on creating access modalities and accelerating exploitation of both underutilized and established rich data sources, to test innovative methods for integrated and vaccine specific benefit risk assessment, and to undertake real life studies from the outset of the project.

Consortium: The ADVANCE Consortium is designed to engage all stakeholders in Europe, while ensuring project feasibility by careful selection of a small group of 15 partners driving progress.. The ADVANCE consortium comprises partners in multiple domains that collectively will allow us to achieve the goals of the call. The first domain consists of European and national organizations responsible for vaccine product assessment and program evaluation. The second domain comprises renowned scientists at the forefront of providing innovative solutions for integrated vaccine outcome assessment. The third domain represents organizations with access to electronic health care records of large populations and with ample expertise in the statistical analysis of large observational data from a public health and pharmacoepidemiological perspective. Finally, a partner with specific expertise on management, dissemination and exploitation of large, complex biomedical research projects ensures outcome oriented interaction in the Consortium and efficient progress towards the attainment of its vision. Recognizing that all stakeholders need to be involved, ADVANCE has created the associate partner role allowing a wide array of int

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

IMI-JU-07-2012
Vedi altri progetti per questo bando

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinatore

P95
Contributo UE
€ 544 004,00
Indirizzo
DIESTSEVEST 125
3000 LEUVEN
Belgio

Mostra sulla mappa

Regione
Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (28)

Il mio fascicolo 0 0